While it may feel like a disease of the past, tuberculosis surged back with a devastating global impact in 2022, sickening an estimated 10.6 million people and claiming 1.6 million lives.
Key Takeaways
- In 2022, an estimated 10.6 million people (including 5.8 million women and 1.3 million children) developed tuberculosis (TB) worldwide, marking a 4.5% increase from 2021.
- Tuberculosis caused an estimated 1.3 million deaths among HIV-negative people in 2022, with a total of 1.6 million deaths including those with HIV.
- The global TB incidence rate fell by 8.3% between 2015 and 2022, from 171 to 157 new cases per 100,000 population.
- Airborne transmission of Mycobacterium tuberculosis occurs primarily through inhalation of droplet nuclei generated by coughs, sneezes, or talking.
- People with latent TB infection exhale far fewer infectious particles than those with active pulmonary TB.
- Close contacts of active TB cases have a 10-30% risk of becoming infected if untreated.
- Xpert MTB/RIF assay detects TB with 85% sensitivity in smear-positive cases and 68% in smear-negative.
- Culture-based diagnosis remains the gold standard for TB, with >90% sensitivity but 2-6 week turnaround.
- Chest X-ray shows abnormalities in 90% of pulmonary TB cases, but specificity is only 60-70%.
- 6-month standard short-course regimen cures 85% of new drug-susceptible TB cases.
- Treatment success rate for new pulmonary TB cases was 88% globally in 2022.
- MDR-TB treatment success is 62% with 9-20 month individualized regimens.
- BCG vaccination at birth prevents 50% of TB deaths in children under 5.
- TB vaccine pipeline includes 17 candidates in clinical trials, with M72/AS01E showing 50% efficacy against pulmonary TB.
- Isoniazid preventive therapy (6H) reduces risk of active TB by 35% in PLHIV.
Tuberculosis cases are rising again but global progress remains far off target.
Diagnosis
1Xpert MTB/RIF assay detects TB with 85% sensitivity in smear-positive cases and 68% in smear-negative.
Verified2Culture-based diagnosis remains the gold standard for TB, with >90% sensitivity but 2-6 week turnaround.
Verified3Chest X-ray shows abnormalities in 90% of pulmonary TB cases, but specificity is only 60-70%.
Verified4IGRA tests (e.g., QuantiFERON) have 90% specificity for latent TB infection, superior to TST (70%).
Directional5Sputum smear microscopy detects 50-60% of TB cases, missing many smear-negative pulmonary TB.
Single source6GeneXpert Ultra improves sensitivity to 90% for smear-negative, HIV-associated TB.
Verified7Urine LAM assay detects TB in 60% of HIV-positive hospitalized patients with CD4 <100.
Verified8Digital chest radiography with AI algorithms achieves 95% sensitivity and 85% specificity for TB screening.
Verified9TST conversion rates in exposed children indicate recent infection, with >10mm induration positive.
Directional10Molecular tests like MTBDRplus detect rifampicin resistance with 96% sensitivity and 99% specificity.
Single source11C-reactive protein >10 mg/L combined with clinical symptoms predicts active TB with 80% accuracy.
Verified12Truenat MTB assay, a chip-based PCR, has 85% sensitivity for pulmonary TB detection.
Verified13Bronchoalveolar lavage culture yields 85-95% sensitivity for pulmonary TB diagnosis.
Verified14Host biomarker signatures (e.g., IP-10, IL-6) distinguish active from latent TB with 85% accuracy.
Directional15Stool Xpert detects extrapulmonary TB in children with 67% sensitivity vs. 47% for gastric aspirate.
Single source16PET-CT imaging shows 89% sensitivity for detecting active TB lesions in extrapulmonary sites.
Verified17Loop-mediated isothermal amplification (LAMP) for TB has 78% sensitivity and 98% specificity vs. culture.
Verified18Adenosine deaminase (ADA) in pleural fluid >40 IU/L indicates TB empyema with 90% sensitivity.
Verified19Nucleic acid amplification tests (NAATs) endorsed by WHO detect TB in 90% of rifampicin-resistant cases.
Directional20Algorithmic diagnosis using symptom screen + chest X-ray detects 92% of TB cases in community screening.
Single source21CRISPR-based diagnostics like DETECTR achieve 95% specificity for TB DNA detection.
Verified22Interferon-gamma release assays boost specificity to 99% in BCG-vaccinated populations.
Verified23Yield of contact tracing investigations: 20-30% of child contacts <5 years found to have active TB.
Verified24First-line DST for isoniazid shows 94% sensitivity but only 80% for low-level resistance.
DirectionalDiagnosis Interpretation
This bewildering statistical smorgasbord, where gold-standard culture languishes in its slow-motion isolation, AI reads X-rays like a psychic, and we can find TB in everything from stool to pee but still can't get a quick, perfect, cheap answer for everyone, perfectly illustrates that modern TB diagnosis is a masterpiece of ingenuity still desperately searching for a single, elegant solution.
Epidemiology
1In 2022, an estimated 10.6 million people (including 5.8 million women and 1.3 million children) developed tuberculosis (TB) worldwide, marking a 4.5% increase from 2021.
Verified2Tuberculosis caused an estimated 1.3 million deaths among HIV-negative people in 2022, with a total of 1.6 million deaths including those with HIV.
Verified3The global TB incidence rate fell by 8.3% between 2015 and 2022, from 171 to 157 new cases per 100,000 population.
Verified4In 2022, 167 countries reported 7.5 million new TB cases to WHO, up from 5.7 million in 2021, representing 71% of the estimated 10.6 million cases.
Directional5The 10 countries with the largest number of new TB cases in 2022 accounted for 64% of the global total: India (26%), Indonesia (10%), China (6.9%), Philippines (6.8%), Pakistan (6.5%), Nigeria (4.1%), Bangladesh (3.9%), DR Congo (3.3%), Russian Federation (2.7%) and Ethiopia (2.2%).
Single source6TB mortality among HIV-negative people declined by 9.2% between 2015 and 2022 globally.
Verified7An estimated 25% of the world’s population – about 2 billion people – are infected with Mycobacterium tuberculosis (latent TB infection).
Verified8Only about 5–10% of people with healthy immune systems who are infected with TB will develop active TB disease during their lifetime.
Verified9In 2021, 1.28 million people died from TB, including 187 000 people with HIV, representing the second leading infectious disease killer after COVID-19.
Directional10The WHO African Region had the highest TB mortality rate per capita in 2022, at 19 deaths per 100,000 population.
Single source11Global TB funding in 2022 reached US$5.8 billion, only 26% of the US$22 billion Global Plan to End TB target.
Verified12In 2022, only 62% of people with TB who were diagnosed were successfully treated, leaving 4.0 million people undiagnosed and untreated.
Verified13TB incidence in the WHO European Region declined by 13% between 2015 and 2022.
Verified14Children younger than 5 accounted for 84% of the 203 000 TB deaths among children in 2022.
Directional15The global target to reduce TB deaths by 90% by 2025 compared with 2015 levels is off track, with only a 9.2% decline achieved by 2022.
Single source16In low TB burden countries, most TB cases are among migrants from high TB burden countries.
Verified17TB notification rates in the EU/EEA were highest in Romania (70 cases per 100,000 in 2021), followed by Latvia (49) and Lithuania (37).
Verified18In the United States, TB incidence was 2.4 cases per 100,000 population in 2022.
Verified19Globally, multidrug-resistant TB (MDR-TB) affects about 410,000 people annually.
Directional20TB is the leading cause of death among people living with HIV, accounting for 1 in 5 HIV-related deaths.
Single source21In 2022, India had 2.8 million estimated new TB cases, representing 26% of the global burden.
Verified22The incidence rate of TB in South Africa was 468 per 100,000 in 2022.
Verified23TB case notifications increased by 6% globally from 2021 to 2022.
Verified24Only 42% of the 30 million people needing TB preventive treatment between 2022 and 2024 are on track to receive it.
Directional25In 2022, 1.25 million women developed TB, with 70% of cases in the 25 highest-burden countries.
Single source26TB incidence among children under 5 declined by only 6% from 2015-2022, compared to 8.3% overall.
Verified27The global TB case detection rate reached 71% in 2022, up from 67% pre-COVID-19 pandemic.
Verified28In the WHO South-East Asia Region, TB incidence fell by only 4.8% between 2015 and 2022.
Verified29An estimated 10.6 million incident TB cases in 2022 included 1.3 million children under 15 years.
DirectionalEpidemiology Interpretation
The numbers reveal a frustrating paradox: while we're slowly bending the curve of TB overall, with global incidence and mortality inching down, the disease remains a staggering, relentless killer—claiming 1.6 million lives, disproportionately affecting the vulnerable, and thriving on a massive funding and treatment gap that leaves millions undiagnosed and a world dangerously off track from its own goals.
Prevention
1BCG vaccination at birth prevents 50% of TB deaths in children under 5.
Verified2TB vaccine pipeline includes 17 candidates in clinical trials, with M72/AS01E showing 50% efficacy against pulmonary TB.
Verified3Isoniazid preventive therapy (6H) reduces risk of active TB by 35% in PLHIV.
Verified4Contact management screens 1.3 million children annually, preventing 200,000 TB cases via TPT.
Directional5Airborne infection control (ventilation, UV lights) reduces TB transmission by 50-70% in healthcare settings.
Single source6TPT scale-up could avert 2.7 million TB deaths and 39 million cases by 2035.
Verified7Active case finding in prisons detects 3x more TB cases than passive surveillance.
Verified8Nutritional supplementation reduces TB incidence by 20% in high-risk groups.
Verified9HIV testing and ART initiation prevents 30% of TB deaths in co-infected individuals.
Directional10M72/AS01E vaccine prevented 49.7% of bacteriologically confirmed pulmonary TB in IGRA+ adults.
Single source11Household contact tracing identifies 15% active TB prevalence in high-burden countries.
Verified12Smoking cessation programs reduce TB risk by 30% within 5 years post-quitting.
Verified13Rapid diagnostic rollout could close 2.5 million detection gap annually.
Verified14TPT for household contacts <5 years prevents 60% progression to active disease.
Directional15Digital adherence technologies increase TPT completion from 65% to 85%.
Single source16Community-wide TPT in high-burden settings averts 20-30% incidence decline over 5 years.
Verified17UVGI systems in HVAC reduce viable TB bacilli by 90% in room air.
Verified18Diabetes screening and control in TB patients reduces mortality by 25%.
VerifiedPrevention Interpretation
The sobering math of TB reveals a clear formula: while the bacteria are formidable, our arsenal of vaccines, treatments, and public health strategies consistently proves that for every grim statistic, there's a human intervention waiting to cut it neatly in half.
Transmission
1Airborne transmission of Mycobacterium tuberculosis occurs primarily through inhalation of droplet nuclei generated by coughs, sneezes, or talking.
Verified2People with latent TB infection exhale far fewer infectious particles than those with active pulmonary TB.
Verified3Close contacts of active TB cases have a 10-30% risk of becoming infected if untreated.
Verified4HIV-positive individuals are 18 times more likely to develop active TB disease than HIV-negative individuals.
Directional5Smoking doubles the risk of TB disease and death, with 0.54 million TB deaths attributable to smoking in 2022.
Single source6Alcohol use disorders increase TB risk by 2-3 times, contributing to 0.75 million TB deaths in 2022.
Verified7Malnutrition accounts for 1.9 million TB deaths annually, tripling the risk of TB infection progressing to disease.
Verified8Diabetes doubles the risk of developing active TB and increases TB mortality by 50%.
Verified9Household contacts of TB patients have up to 50% infection rate in high-burden settings.
Directional10TB spreads more efficiently in crowded, poorly ventilated indoor spaces with low humidity.
Single source11Children under 5 years are at highest risk of progressing from infection to severe disseminated TB disease quickly.
Verified12People with silicosis have a 30-fold increased risk of developing active TB.
Verified13Undernutrition increases TB risk by 4-6 times, with BMI <18.5 kg/m² elevating odds.
Verified14In prisons, TB transmission risk is 100 times higher than in general population due to overcrowding.
Directional15HIV/TB co-infection accelerates TB progression, with 6% annual risk of active TB in dually infected individuals.
Single source16Tobacco smoking increases TB infection risk by 50% and disease progression by 2-3 times.
Verified17Air pollution contributes to 15% of global TB burden, exacerbating lung vulnerability to M. tuberculosis.
Verified18Pregnant women with TB have 3 times higher risk of maternal mortality.
Verified19People living with both HIV and TB are 18 (10–27) times more likely to die from TB.
Directional20In high-burden settings, 20-30% of household contacts develop latent TB infection after exposure.
Single source21Drug users injecting substances have 3 times higher TB risk due to immune suppression.
Verified22Chronic kidney disease increases TB risk 5-10 fold.
Verified23TNF-alpha inhibitors used in autoimmune diseases increase active TB risk 4-fold.
Verified24The basic reproduction number (R0) for TB in high-prevalence settings is 2-3 without interventions.
Directional25Sputum-positive TB patients infect 5-15 contacts on average over their infectious period.
Single sourceTransmission Interpretation
This grim symphony of statistics makes it abundantly clear that tuberculosis thrives not just on the bacterium itself, but on a chorus of social inequities and comorbidities, transforming it from a mere infection into a brutal barometer of human vulnerability.
Treatment
16-month standard short-course regimen cures 85% of new drug-susceptible TB cases.
Verified2Treatment success rate for new pulmonary TB cases was 88% globally in 2022.
Verified3MDR-TB treatment success is 62% with 9-20 month individualized regimens.
Verified4BPaLM regimen (bedaquiline, pretomanid, linezolid, moxifloxacin) achieves 89-94% success in 6 months for MDR-TB.
Directional5Pretomanid reduces treatment duration for XDR-TB from 20 to 6 months with 91% favorable outcomes.
Single source6Isoniazid preventive therapy (IPT) reduces TB incidence by 60% in PLHIV.
Verified7Rifampicin-based 4-month regimen for drug-susceptible TB shows 90% success vs. 86% for 6-month.
Verified8Delamanid added to MDR-TB regimen increases culture conversion by 20% at month 2.
Verified9Linezolid in MDR-TB regimens yields 85% success but with 40% adverse event rate.
Directional10Shorter 9-12 month MDR-TB regimen success rate: 85% vs. 67% for longer regimens.
Single source11TB treatment dropout rate is 13% globally, contributing to 400,000 resistance cases yearly.
Verified12Adherence support via video-observed therapy (VOT) improves success by 10% over DOT.
Verified13Fluoroquinolone-containing regimens for TB meningitis reduce mortality by 25%.
Verified14Pretomanid Nix-TB trial: 96% interim success at 6 months for fluoroquinolone-sensitive MDR-TB.
Directional15Isoniazid + rifapentine 1HP regimen for latent TB has 93% completion rate and 86% efficacy.
Single source16Surgery for MDR-TB (lobectomy) improves success from 50% to 85% in localized disease.
Verified17High-dose rifampicin (35mg/kg) accelerates sputum conversion by 20% at week 8.
Verified18Cycloserine in MDR-TB regimens requires therapeutic drug monitoring due to 40% neuropsychiatric toxicity.
Verified193HP regimen (3 months isoniazid+rifapentine) prevents TB 76% effectively in contacts.
Directional20BPaL regimen interim success 93% at 6 months for extensively drug-resistant TB.
Single source21Treatment success for children with TB is 82%, lower due to diagnosis challenges.
Verified22Levofloxacin substitution in short-course regimens maintains 90% efficacy with fewer side effects.
VerifiedTreatment Interpretation
In the relentless battle against tuberculosis, our arsenal is sharpening dramatically—shorter, smarter regimens are pushing cure rates into the 90s, while stubborn gaps in adherence and toxicity remind us that even brilliant science cannot cure what it doesn't reach.
Sources & References
- Reference 1WHOwho.intVisit source
- Reference 2CDCcdc.govVisit source
- Reference 3ECDCecdc.europa.euVisit source
- Reference 4UNAIDSunaids.orgVisit source
- Reference 5TBCINDIAtbcindia.gov.inVisit source
- Reference 6NCBIncbi.nlm.nih.govVisit source
- Reference 7ILOilo.orgVisit source
- Reference 8NEJMnejm.orgVisit source
- Reference 9THELANCETthelancet.comVisit source
- Reference 10NATUREnature.comVisit source
- Reference 11COCHRANELIBRARYcochranelibrary.comVisit source